139 related articles for article (PubMed ID: 33060390)
1. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
Zar T; Tschernatsch M; Hero B; Lang B; Preissner KT; Blaes F
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e176-e179. PubMed ID: 33060390
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
Blaes F; Pike MG; Lang B
J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H
J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235
[TBL] [Abstract][Full Text] [Related]
4. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
Korfei M; Fühlhuber V; Schmidt-Wöll T; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2005 Dec; 170(1-2):150-7. PubMed ID: 16203043
[TBL] [Abstract][Full Text] [Related]
5. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
[TBL] [Abstract][Full Text] [Related]
6. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
Raffaghello L; Conte M; De Grandis E; Pistoia V
Eur J Paediatr Neurol; 2009 May; 13(3):219-23. PubMed ID: 18571942
[TBL] [Abstract][Full Text] [Related]
7. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
8. IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Ding X; Han W; Wang J; Yang W; Chang XF; Zhu ZY; Qin H; Zhang JZ; Wang X; Wang HM
Pediatr Res; 2019 May; 85(6):885-894. PubMed ID: 30718793
[TBL] [Abstract][Full Text] [Related]
9. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
Blaes F; Dharmalingam B
Expert Rev Neurother; 2016 Jun; 16(6):641-8. PubMed ID: 27095464
[TBL] [Abstract][Full Text] [Related]
10. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
[TBL] [Abstract][Full Text] [Related]
11. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F
Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
[TBL] [Abstract][Full Text] [Related]
12. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.
Pranzatelli MR; Tate ED; McGee NR
Pediatr Blood Cancer; 2018 Aug; 65(8):e27097. PubMed ID: 29727049
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
Fühlhuber V; Bick S; Tschernatsch M; Dharmalingam B; Kaps M; Preissner KT; Blaes F
J Neuroimmunol; 2015 Dec; 289():182-6. PubMed ID: 26616889
[TBL] [Abstract][Full Text] [Related]
15. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome].
Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062
[TBL] [Abstract][Full Text] [Related]
16. Presence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with opsoclonus-myoclonus syndrome associated with neuroblastoma.
Noguchi K; Ikawa Y; Takenaka M; Sakai Y; Fujiki T; Kuroda R; Ikeda H; Nakada S; Nomura K; Sakai S; Fukuda M; Araki R; Takahashi Y; Wada T
Pediatr Hematol Oncol; 2023 May; 40(4):363-370. PubMed ID: 36125271
[TBL] [Abstract][Full Text] [Related]
17. Opsoclonus-myoclonus syndrome associated with neuroblastoma: Insights into antitumor immunity.
Du H; Cai W
Pediatr Blood Cancer; 2022 Nov; 69(11):e29949. PubMed ID: 36094353
[TBL] [Abstract][Full Text] [Related]
18. Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma.
Amini A; Lang B; Heaney D; Irani SR
Neurology; 2016 Aug; 87(6):634-6. PubMed ID: 27385747
[No Abstract] [Full Text] [Related]
19. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.
Armangué T; Sabater L; Torres-Vega E; Martínez-Hernández E; Ariño H; Petit-Pedrol M; Planagumà J; Bataller L; Dalmau J; Graus F
JAMA Neurol; 2016 Apr; 73(4):417-24. PubMed ID: 26856612
[TBL] [Abstract][Full Text] [Related]
20. Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome.
Petit-Pedrol M; Guasp M; Armangue T; Lavarino C; Morales La Madrid A; Saiz A; Graus F; Dalmau J
Neurology; 2021 Feb; 96(7):e1082-e1087. PubMed ID: 33443132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
